An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Repertoire Immune Medicines
Study ID
NCT07293754
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Malignant Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RPTR-1-201 — DRUG
    RPTR-1-201
  • PD-1 / PD-L1 monoclonal antibody — DRUG
    PD-1/PD-L1 monoclonal antibody

Study Details

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.

Key Dates

Start date
Dec 12, 2025
Status verified
Feb 2026
Primary completion
Dec 15, 2028
Completion
Apr 15, 2029

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy
    Participants receive RPTR-1-201 at doses and schedules defined by the trial protocol.
  • Experimental: Combination
    Participants receive RPTR-1-201 in combination with an approved or investigational PD-1 monoclonal antibody at doses and schedules defined by the trial protocol.

Primary Outcome Measure

Number of participants with dose-limiting toxicities and treatment-emergent adverse events. [ Time Frame: From first dose through 30 days after last dose of trial treatment. ]

Locations (1)

FacilityCityStateZIPSite coordinators
START MidwestGrand RapidsMichigan49546
Jacob Goldberg
[email protected]
616-954-5561

Find similar trials in Grand Rapids, MI

By research site
START Midwest· Grand Rapids, MI

Related Studies